Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Oncology-focused biotech company Guardant Health is partnering with AI drug development company Zephyr AI to combine AI and ...

Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...

Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing ...

The researchers argue that the integration of explainable AI into clinical decision-making pipelines could reshape cancer ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...

Sometimes the unintended consequences of a treatment can seem worse than the disease. That's certainly the case for patients ...

Cancer treatment is no longer limited to standard protocols . The same drug, given in the same way, does not work for every ...

Adding the antiangiogenic drug to standard care does not extend overall survival among patients with metastatic esophageal ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

An AI system has been designed to aid cancer diagnosis, providing insights into subtyping, biomarker quantification, ...